Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
4D Molecular Therapeutics Inc (FDMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: FDMT (1-star) is a SELL. SELL since 2 days. Profits (-0.78%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $31.1
1 Year Target Price $31.1
| 5 | Strong Buy |
| 4 | Buy |
| 2 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.24% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 177.89M USD | Price to earnings Ratio - | 1Y Target Price 31.1 |
Price to earnings Ratio - | 1Y Target Price 31.1 | ||
Volume (30-day avg) 12 | Beta 2.83 | 52 Weeks Range 2.23 - 28.93 | Updated Date 06/30/2025 |
52 Weeks Range 2.23 - 28.93 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -383007.15% |
Management Effectiveness
Return on Assets (TTM) -22.19% | Return on Equity (TTM) -32.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -119697375 | Price to Sales(TTM) 7734.19 |
Enterprise Value -119697375 | Price to Sales(TTM) 7734.19 | ||
Enterprise Value to Revenue 8.57 | Enterprise Value to EBITDA -3.55 | Shares Outstanding 46324600 | Shares Floating 35394806 |
Shares Outstanding 46324600 | Shares Floating 35394806 | ||
Percent Insiders 3.88 | Percent Institutions 95.91 |
Analyst Ratings
Rating 4 | Target Price 31.1 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
4D Molecular Therapeutics Inc
Company Overview
History and Background
4D Molecular Therapeutics (4DMT) was founded in 2013. It's a clinical-stage biotherapeutics company focusing on the discovery and development of targeted, evolved AAV gene therapies for patients with severe genetic diseases. They use their Therapeutic Vector Evolution platform to design vectors for tissue-specific delivery.
Core Business Areas
- AAV Gene Therapy: Develops gene therapies using adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to target cells.
- Therapeutic Vector Evolution: Utilizes a proprietary platform to design and optimize AAV vectors for improved tissue specificity and reduced off-target effects.
Leadership and Structure
David Kirn, M.D., is the Co-founder and Chief Executive Officer. The company has a typical biotech structure with research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- 4D-150: A gene therapy candidate for wet age-related macular degeneration (wet AMD). Currently in clinical trials. Competitors include Regeneron (EYLEA), Roche/Genentech (Lucentis, Vabysmo), and other gene therapy companies like Adverum Biotechnologies and REGENXBIO.
- 4D-310: A gene therapy candidate for Fabry disease. Currently in clinical trials. Competitors include Sanofi (Fabrazyme), Takeda (Replagal), and Amicus Therapeutics (Galafold) for enzyme replacement therapy and gene therapy companies like AVROBIO and Freeline Therapeutics.
- 4D-710: A gene therapy candidate for cystic fibrosis (CF). Currently in clinical trials. Competitors include Vertex Pharmaceuticals (Trikafta) and other gene therapy companies pursuing CF treatments.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing regulatory approvals. It addresses unmet needs in treating genetic diseases and cancers. High development costs and regulatory hurdles remain challenges.
Positioning
4DMT aims to be a leader in AAV gene therapy through its Therapeutic Vector Evolution platform, which focuses on vector design to improve efficacy and safety. They have a diversified pipeline targeting different diseases.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to reach tens of billions of dollars. 4DMT is positioning itself to capture a significant share of this market by focusing on targeted therapies for diseases with unmet needs. Estimates vary greatly by indication and success of pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary Therapeutic Vector Evolution platform
- Diversified pipeline targeting multiple indications
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical trial risks and potential for failure
- High R&D costs and long development timelines
- Reliance on third-party manufacturing
- Limited commercial experience
Opportunities
- Positive clinical trial data leading to regulatory approval
- Expansion of pipeline into new indications
- Strategic partnerships and collaborations
- Potential for acquisition by a larger pharmaceutical company
Threats
- Competition from other gene therapy companies
- Regulatory hurdles and delays
- Unfavorable changes in reimbursement policies
- Safety concerns associated with gene therapy
Competitors and Market Share
Key Competitors
- AVRO (AVRO)
- REGENXBIO (RGNX)
- VERX (VERX)
- CRSP (CRSP)
- BLUE (BLUE)
Competitive Landscape
The gene therapy space is highly competitive. 4DMT differentiates itself with its Therapeutic Vector Evolution platform. However, there are several companies developing gene therapies for the same indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by pipeline advancement and expansion. The company has grown significantly since its inception.
Future Projections: Future growth is tied to the success of its clinical trials and regulatory approvals. Analyst estimates vary widely based on risk assessments of their pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for 4D-150, 4D-310, and 4D-710, expanding its pipeline, and forming strategic collaborations.
Summary
4DMT is a promising clinical-stage gene therapy company with a novel platform and diversified pipeline. Success hinges on positive clinical trial results and regulatory approvals. The company faces significant competition and high R&D costs, requiring continued access to capital and strategic partnerships to succeed in the competitive gene therapy market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor. Market share data is approximate and may vary depending on the source and definition.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 4D Molecular Therapeutics Inc
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2020-12-11 | Co-Founder, CEO & Director Dr. David H. Kirn M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 227 | |
Full time employees 227 | |||
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.